Skip to main content

Table 1 Baseline demographics of patients receiving at least one dose of infliximab

From: 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis

Characteristic Value
Age (years) (n = 575)  
   Mean ± SD 57 ± 13
   Median 58
   Range 19 -99
Sex  
   Female, N (%) 419 (72.9%)
   Male, N (%) 156 (27.1%)
Age at diagnosis (years) (n = 564)  
   Mean ± SD 46.2 ± 13.6
   Median 47
   Range 5-81
Duration of disease (years) (n = 564)  
   Mean ± SD 10.3 ± 9.4
   Median 8
   Range 0-53
HAQ index at screening (n = 573)  
   Mean ± SD 56.1 ± 15.4
   Median 55
   Range 2-98
Swollen joint count at screening (n = 568)  
   Mean ± SD 16.3 ± 7.5
   Median 14
   Range 0-49
MTX doses in mg/week (n = 425)  
   Mean ± SD 14.5 ± 3.0
   Median 15
   Range 5-25
MTX use  
   Yes, N (%) 537 (93.4%)
   No, N (%) 14 (2.4%)
   Unknown, N (%) 24 (4.2%)
NSAID use  
   Yes, N (%) 414 (72%)
   No, N (%) 46 (8%)
   Unknown, N (%) 115 (20%)
Corticosteroid use  
   Yes, N (%) 341 (59.3%)
   No, N (%) 84 (14.6%)
   Unknown, N (%) 150 (26.1%)
  1. HAQ, health assessment questionnaire; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; SD, standard deviation.